Andreas Hagen Røssevold

7PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 25, 2025
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy.

Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen

|Jun 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.

Andreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde

|Nov 15, 2024
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold

|Apr 23, 2024
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.

Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen

|Jan 19, 2024
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur

|Dec 09, 2022
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.

Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre

Pageof 2

Frequent Collaborators

6 joint publications

Jon Amund Kyte

5 joint publications

Nikolai Kragøe Andresen

3 joint publications

Bjørn Naume

2 joint publications

Xavier Tekpli